Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-20,268
Closed -$236K 3279
2024
Q1
$236K Buy
+20,268
New +$224K ﹤0.01% 3000
2023
Q2
Sell
-4,015
Closed -$61.1K 3736
2023
Q1
$61.1K Sell
4,015
-287,010
-99% -$3.74M ﹤0.01% 3530
2022
Q4
$3.7M Buy
291,025
+248,208
+580% +$2.23M 0.02% 1296
2022
Q3
$248K Buy
42,817
+17,475
+69% +$76.8K ﹤0.01% 3628
2022
Q2
$82K Buy
25,342
+6,410
+34% +$19.4K ﹤0.01% 4016
2022
Q1
$71K Buy
+18,932
New +$122K ﹤0.01% 3313
2021
Q2
Sell
-13,560
Closed -$321K 2959
2021
Q1
$321K Buy
+13,560
New +$313K ﹤0.01% 2214
2020
Q4
Sell
-6,280
Closed -$161K 2593
2020
Q3
$161K Buy
6,280
+4,707
+299% +$149K ﹤0.01% 2188
2020
Q2
$31K Buy
+1,573
New +$38.2K ﹤0.01% 2296

Other funds holding ETNB

Cubist Systematic Strategies's ETNB Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of 89bio (ETNB) in Q2 2024, closing a stake of 20,268 shares — an estimated $236K sold.

Cubist Systematic Strategies first reported a position in ETNB in Q2 2020 and held it in 9 quarters. The position peaked at $3.7M in Q4 2022. 145 funds tracked by Wall St. Rank hold ETNB as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining 89bio position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 20,268 89bio shares in Q2 2024, an estimated $236K.
  • Cubist Systematic Strategies first reported a position in 89bio in Q2 2020 and held it in 9 quarters.
  • Cubist Systematic Strategies's 89bio position peaked at $3.7M in Q4 2022.
  • 145 funds tracked by Wall St. Rank held 89bio as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.